A protein that slashes the survival rates of head and neck cancer sufferers has been discovered - leaving scientists feeling positive that it could be vital for future treatment to help prevent cancer tumours developing.
Researchers from the Fox Chase Cancer Center in Philadelphia found patients with head and neck cancer tumours had higher levels of the protein known as Aurora-A.
The study compared the survival rates of those with high and normal levels of the Aurora-A protein and discovered that those carrying above average levels had shorter survival rates following surgery to remove the tumour.
Following this discovery, scientists created a compound that targets this protein- the same protein which has also been associated with genitourinary, gastrointestinal, breast and lung cancer.
"This finding suggests Aurora-A does play a role in the development of had and neck cancers," says study author Christian J.Fidler in a statement. "Consequently, Aurora-A represents another potential target for additional therapies."
The Aurora-A protein is believed to fuel tumour growth, as it helps carry signals from a protein on the surface of the cell called EGFR which encourages cancer cells to grow or divide.
Another study by the same university also made a breakthrough 'biomarker' protein discovery linked to the survival rate of pancreatic cancer, this time focusing on the protein called survivin.
For patients diagnosed with pancreatic cancer, the five-year survival rate is barely 20%. However, scientists have discovered a key protein that could identify how likely a patient is to survive and how well they respond to treatment.
The role of survivin, a protein that blocks apoptosis (cell death), was investigated further as researchers studied 88 patients with pancreatic cancer. They discovered that those with higher levels of surviving lived longer after receiving the chemotherapy drug gemcitabine and radiation therapy (5-FU).
"Biomarkers for pancreatic cancer are especially useful because the survival is o poor and it's such a bad disease for people to get," explains Saad Khan from the study. "We want to see if there are drugs that work better in patients with surviving than in those who don't have it."
Researchers added that although the findings are a long way off from drawing a line under whether survivin helps prevent pancreatic cancer, they feel positive that it will pave the way for further research into the subject.
"In terms of overall survival, patients treated with chemotherapy or radiation did better when they had higher amounts of survivin which goes against what we'd expected, but this did not achieve statistical significance.
"Our results suggest that people with higher levels of survivin responded better to specific chemotherapies.
"There's a lot of work being done in biomarkers for more aggressive cancers, like pancreatic," Khan explains.
Researchers from the Fox Chase Cancer Center also looked into the role of two other proteins that could play a crucial role in treating breast cancer.
The study discovered that the proteins STAT-1 and PLSCR-1 help restore the body's sensitivity towards the resistance against cancerous cells.
The proteins are 20 times more likely to appear in breast cancer cells that are resistant to oestrogen deprivation than in cancer cells that die without oestrogen. This is significant because oestrogen is the hormone that fuels cancerous cell growth.
"The models we've developed in the lab are reflective of what happens in the clinic when you have patients with hormone-dependent disease," says study author Joan Lewis-Wambi in a statement. "Initially they respond to treatment, but over time the disease becomes resistant to the drug, and the drug no longer works."
Scientists are hoping to use these proteins in treatment that help cells become less resistant to oestrogen-depriving drugs and help that cancerous cells die.
"Our goal is to identify the genes that make patients more or less likely to respond to a drug," explains Lewis-Wambi.
All findings were presented AACR Annual Meeting 2012.
A twice-daily skin cancer drug almost doubles the survival times of advanced cancer patients, American scientists have discovered. Researchers from the Jonsson Cancer Center at the University of California, found that advanced melanoma cancer sufferers lived on average of 16 months after receiving the vemurafenib drug. Read the full story here. Read the full story here
Scientists have discovered five new genes that cause heart attacks and strokes and hope these findings will enable them to pinpoint when the attacks will strike. The researchers, from Queen Mary University of London, identified five generic variants that trigger heart attacks and strokes after investigating blood pressure measurements of 25,000 participants. The aim of the study was to look into the role that genes play in hypertension and high blood pressure. Read the full story here.
American scientists have discovered a potential new drug that could help fight against Alzheimer's disease. Neuroscientists from the Case Western Reserve University School of Medicine discovered that a skin cancer drug called bexarotene appears to reverse cognitive and memory deficits associated with Alzheimer's when tested on lab mice. Read the full story here.
A "personalised" pill for advanced skin cancer that can extend life has been approved for use in the UK. The drug, vemurafenib, only works for patients with a specific variant of the BRAF gene. Read the full story here.
The genetic code of the most common form of hereditary breast cancer has been mapped for the first time, offering hope for diagnosis and treatment of the disease in the future. Researchers say they have "fully sequenced" the DNA of two breast cancers caused by a faulty BRCA1 gene, which is responsible for aggressive and highly drug-resistant tumours. Read the full story here.
Scientists from the Northwestern University in Chicago have come one step closer to developing a potential cure for peanut allergies, by creating an immune system tolerant to peanuts. The researchers found that they can switch off potentially deadly peanut allergy attacks by tricking the immune system into tolerating nut proteins, and not seeing them as a threat to the body. Read the full story here.
A breakthrough lung cancer detection test is set to be trialled on smokers for the first time in Scotland. If successful, cancers could be identified five years earlier than by current detection methods. Read the full story here.
Sleepless nights could soon be a thing of the past as scientists discover a key chemical trigger that suppresses sleep and wakes people up. Researchers from Boston University found that when the body has too little of the calcium kinase enzyme, it causes the brain to nod off to sleep. Read the full story here.
A new treatment for breast cancer has been discovered after scientists found that breast tumours can be killed in minutes - by boiling them. The latest treatment, known as Preferential Radio-Frequency Ablation, uses a targeted electrical current that heats, or 'boils' the tumour to 70 to 90c (160 to 190f). Read the full story here.
British scientists have developed a revolutionary breast-screening system that uses anti-landmine technology to detect cancer in seconds. The radio-wave scanner is safer, cheaper and less painful than traditional mammogram X-rays, and unlike the current system, can be used on women of all ages. Read the full story here.
Breakthrough research involving a brain transplant of stem cells could offer hope for the treatment of both autism and Parkinson's disease. The study, from Harvard University, has already proven successful with mice. Scientists transferred healthy stem cells from mouse embryos into the brains of adult mice who were unable to use leptin, a hormone that tells the body when to stop eating. Read the full story here.
A stomach implant that can trick the brain into thinking the stomach is full is the latest hi-tech gadget that experts hope will help fight the flab and beat obesity. The Abiliti, or 'Gastric Pacemaker', is a credit card-sized implant, inserted using keyhole surgery, which detects when food has been eaten and sends signals to the brain to create the feeling of fullness. Read the full story here.
Scientists from the Imperial College London have discovered a 'fertility switch' that could help treat infertility and miscarriage in the future. The study, published in the Nature Medicine journal, discovered an enzyme in the body that determines infertility and the chances of miscarriage, as it acts like a 'switch'. Read the full story here.
Eviplera, a new once-daily pill for the treatment of HIV has been made available in 27 countries of the European Union following approval by the European Medicines Agency. The new drug, from Gilead Sciences, combines three antiretroviral treatments in a single tablet so HIV patients only need to take one tablet a day to treat their condition. Read the full story here.
Scientists believe that a potent Alzheimer's vaccine jab could be the secret to preventing the disease developing from its early stages. Researchers from Georgetown University Medical Center in Washington found that an antibody for Alzheimer's disease is more likely to trigger inflammation in the brain the later it is given and that it could potentially be prevented, as long as the vaccine is taken during the very early stages of the disease. Read the full story here.